Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Published 11 November 2008, doi:10.1136/bmj.a2423
Cite this as: BMJ 2008;337:a2423
Jorie Versmissen, researcher1, Daniëlla M Oosterveer, researcher1, Mojgan Yazdanpanah, epidemiologist1, Joep C Defesche, senior researcher2, Dick C G Basart, clinician3, Anho H Liem, clinician4, Jan Heeringa, statistician5, Jacqueline C Witteman, professor of epidemiology5, Peter J Lansberg, clinician2, John J P Kastelein, professor of vascular medicine2, Eric J G Sijbrands, associate professor1
1 Department of Internal Medicine, Erasmus University Medical Centre, PO box 2040, 3000 CA Rotterdam, Netherlands, 2 Department of Vascular Medicine, Academic Medical Centre, PO box 22660, 1100 DD Amsterdam, Netherlands, 3 Department of Cardiology, Westfries Gasthuis, PO box 600, 1620 AR Hoorn, Netherlands, 4 Department of Cardiology, Oosterschelde Hospital, PO box 106, 4460 BB Goes, Netherlands, 5 Department of Epidemiology and Biostatistics, Erasmus University Medical Centre, Rotterdam
Correspondence to: E J G Sijbrands e.sijbrands{at}erasmusmc.nl
Design Cohort study with a mean follow-up of 8.5 years.
Setting 27 outpatient lipid clinics.
Subjects 2146 patients with familial hypercholesterolaemia without prevalent coronary heart disease before 1 January 1990.
Main outcome measures Risk of coronary heart disease in treated and "untreated" (delay in starting statin treatment) patients compared with a Cox regression model in which statin use was a time dependent variable.
Results In January 1990, 413 (21%) of the patients had started statin treatment, and during follow-up another 1294 patients (66%) started after a mean delay of 4.3 years. Most patients received simvastatin (n=1167, 33 mg daily) or atorvastatin (n=211, 49 mg daily). We observed an overall risk reduction of 76% (hazard ratio 0.24 (95% confidence interval 0.18 to 0.30), P<0.001). In fact, the risk of myocardial infarction in these statin treated patients was not significantly greater than that in an age-matched sample from the general population (hazard ration 1.44 (0.80 to 2.60), P=0.23).
Conclusion Lower statin doses than those currently advised reduced the risk of coronary heart disease to a greater extent than anticipated in patients with familial hypercholesterolaemia. With statin treatment, such patients no longer have a risk of myocardial infarction significantly different from that of the general population.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
StumbleUpon
Technorati What's this?
Read all Rapid Responses